Grant: Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream
University of Toronto
$236,234.00
Preclinical characterization of multimeric ribozymes as potential preventive and therapeutic agents for HIV-1 infection
EF 2008-09
Résumé
To prevent HIV transmission in individuals at high risk of HIV infection, the mucosal epithelial cells of the vagina and rectum will be modified using a lentiviral vector to allow continuous local production of proteins that inactivate HIV and render the target cells non-permissive to HIV. CD4 serves as the primary receptor and CCR5 as the major co-receptor for entry by HIV. Therefore, a lentiviral vector will be designed to express a sCD4-FI3 (soluble CD4 fused to a fusion inhibitor) that will coat the virus and render it inactive, and scAbR5 (a single chain antibody to CCR5) that would bind to CCR5 and lead to its internalization as to render the target cells non-permissive to HIV. This vector will be used to transduce cervical epithelial cell lines. We will determine whether the interfering proteins secreted from these cells can inhibit HIV infection. If so, we will determine whether HIV transmission can be blocked in humanized mice that undergo gene therapy.
To inhibit HIV-1 entry/replication in HIV infected individuals, CD4+ T cells, monocytes and CD34+ stem/progenitor cells will be modified using lentiviral vectors expressing multimeric hammerhead ribozymes. Ribozymes are small catalytic RNAs that can be designed to recognize and cleave a specific target RNA. Rz1-7 is targeted against 7 unique sites within the CCR5 mRNA, and Rz1-14 is targeted against 14 highly conserved sites within the HIV-1 RNA. These ribozymes can confer excellent inhibition of HIV-1 entry (Rz1-7) and replication (Rz1-14) in CD4+ T cell lines. We will determine whether CD4+ T cells and monocytes transduced with lentiviral vectors expressing Rz1-7 or Rz1-14 inhibit HIV-1 entry/replication, and exhibit normal cell functions. We will also test whether transduced CD34+ stem/progenitor cells can differentiate normally and whether the differentiated CD4+ T cells and monocytes express ribozymes, confer HIV-1 resistance, possess a survival advantage, and exhibit normal immune functions.
Programme
Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
177340
Name
Joshi Sadhna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Preclinical characterization of multimeric ribozymes as potential preventive and therapeutic agents for HIV-1 infection
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$236,234
Cihrequipment2
$0
Programname2
Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream
Keyworddelim
Aids; Gene Therapy; Hematopoietic Stem Cells; Hiv; Hiv-1 Infections; Multimeric Ribozymes
Abstract
To prevent HIV transmission in individuals at high risk of HIV infection, the mucosal epithelial cells of the vagina and rectum will be modified using a lentiviral vector to allow continuous local production of proteins that inactivate HIV and render the target cells non-permissive to HIV. CD4 serves as the primary receptor and CCR5 as the major co-receptor for entry by HIV. Therefore, a lentiviral vector will be designed to express a sCD4-FI3 (soluble CD4 fused to a fusion inhibitor) that will coat the virus and render it inactive, and scAbR5 (a single chain antibody to CCR5) that would bind to CCR5 and lead to its internalization as to render the target cells non-permissive to HIV. This vector will be used to transduce cervical epithelial cell lines. We will determine whether the interfering proteins secreted from these cells can inhibit HIV infection. If so, we will determine whether HIV transmission can be blocked in humanized mice that undergo gene therapy.
To inhibit HIV-1 entry/replication in HIV infected individuals, CD4+ T cells, monocytes and CD34+ stem/progenitor cells will be modified using lentiviral vectors expressing multimeric hammerhead ribozymes. Ribozymes are small catalytic RNAs that can be designed to recognize and cleave a specific target RNA. Rz1-7 is targeted against 7 unique sites within the CCR5 mRNA, and Rz1-14 is targeted against 14 highly conserved sites within the HIV-1 RNA. These ribozymes can confer excellent inhibition of HIV-1 entry (Rz1-7) and replication (Rz1-14) in CD4+ T cell lines. We will determine whether CD4+ T cells and monocytes transduced with lentiviral vectors expressing Rz1-7 or Rz1-14 inhibit HIV-1 entry/replication, and exhibit normal cell functions. We will also test whether transduced CD34+ stem/progenitor cells can differentiate normally and whether the differentiated CD4+ T cells and monocytes express ribozymes, confer HIV-1 resistance, possess a survival advantage, and exhibit normal immune functions.
Competitiondate
200809
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Joshi, Sadhna
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $236,234~ $0~